trending Market Intelligence /marketintelligence/en/news-insights/trending/WQy9Y3e47jEWswjw1nLqOQ2 content esgSubNav
In This List

Bristol-Myers Squibb drops plans for Opdivo-Yervoy lung cancer combo

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Bristol-Myers Squibb drops plans for Opdivo-Yervoy lung cancer combo

Bristol-Myers Squibb Co. is no longer seeking accelerated approval in the U.S. for its Opdivo-Yervoy combination in first-line lung cancer.

The company based the decision on a "review of data available at this time," it said in a news release. It added that it would not be providing additional details in order to protect the integrity of ongoing registrational studies.